Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism

Yousef Almehmadi, Aksam A. Yassin, Joanne E. Nettleship, Farid Saad

Institute of Urology/Andrology, Norderstedt-Hamburg, Germany
Dresden International University, Dresden, Germany
Gulf Medical University School of Medicine, Ajman, United Arab Emirates
Department of Human Metabolism, University of Sheffield, Sheffield, South Yorkshire, UK
Global Medical Affairs Men’s Healthcare, Bayer Pharma AG, Berlin, Germany

Received 17 August 2015, Received in revised form 9 October 2015, Accepted 24 October 2015
Available online 27 November 2015

Abstract  Objectives: To test the hypothesis that testosterone replacement therapy (TRT) improves the long-term health-related quality of life (HRQoL) of men with late-onset hypogonadism (LOH), as studies have shown that sub-physiological testosterone levels have a negative impact on psychological (e.g. mood, vitality, libido and sexual interest) and physical features (e.g. erectile function and physical strength), all of which contribute to a sense of well-being.

Patients and methods: In all, 261 patients (mean age 58 years) diagnosed with LOH were treated with long-acting intramuscular testosterone undecanoate (TU) for up to 5 years. Health quality indicators including the International Prostate Symptom Score (IPSS), the five-item version of the International Index of Erectile Function (IIEF-5), the Aging Males’ Symptoms (AMS) scale, and the percentage of patients reporting joint and muscle pain were measured at baseline and at each visit. The means were then plotted over time in parallel with mean total testosterone (TT) levels.

Results: Both the mean IPSS and AMS scores fell significantly within the first 3 months and the mean IIEF-5 score and TT levels increased within the first 3 months.

Keywords: Testosterone; Late-onset hypogonadism; Erectile dysfunction; Depression; Obesity

Abbreviations

AMS, Aging Males’ Symptoms (scale); ED, erectile dysfunction; HRQoL, health-related quality of life;

* Corresponding author at: Rathausallee 94a, 22846 Norderstedt-Hamburg, Germany. Tel.: +49 40 526 21 57; fax: +49 40 526 28 20.
E-mail address: yassin@t-online.de (A.A. Yassin).
Peer review under responsibility of Arab Association of Urology.
Late-onset hypogonadism (LOH), as defined by a serum total testosterone (TT) level of ≤12 nmol/L, is diagnosed when declining testosterone concentrations in the ageing male cause unwanted symptoms such as erectile dysfunction (ED), obesity, lack of physical strength, and depressed mood [1–4]. It is thought that almost 40% of men aged >45 years are hypogonadal to some degree [5].

Numerous studies have shown that testosterone levels are closely associated with both erectile function and obesity [6–8]. In fact, the presence of visceral obesity can predict ED [9] and weight loss improves erectile function and testosterone levels [10,11]. Increasing evidence shows that testosterone can reduce both total and visceral body fat [12–16], and is an effective treatment for ED, as measured by the International Index of Erectile Function (IIEF) questionnaire [17–19].

Testosterone also maintains psychological features such as mood, vitality, libido and sexual interest, which contribute greatly to an overall sense of well-being and health-related quality of life (HRQoL). Consequently, in men with LOH there is an increase in symptoms such as dysphoria, low vigour and vitality, diminished libido and orgasm, irritability, poor cognitive function, and increased risk of depression [20–23]. Associations have also been reported between both ED and depression [24], and obesity and depression where obese patients at baseline were at an increased risk of depression at follow-up [25]. Evidence that testosterone can effectively treat symptoms of depression comes from a randomised, placebo-controlled phase III trial in which 184 men with hypogonadism and metabolic syndrome were treated with testosterone undecanoate (TU) for 30 weeks. At the end of the trial period TU was found to have significantly improved depressive symptoms as measured by the Beck Depression Inventory (BDI-IA) [26].

In men undergoing androgen-deprivation therapy for prostate cancer, mood disturbances, anxiety, fatigue, and lack of drive are observed [27]. In a cohort of elderly hypogonadal men in the European Ageing Male Study, low testosterone levels were found to be associated with ED, low sexual desire, poor morning erections, fatigue, and depression [28]. Thus, low testosterone-associated sexual dysfunction has a major impact on HRQoL and emotional well-being [29–31].

Hypogonadal men undergoing testosterone replacement therapy (TRT) show improved parameters of well-being, bone density, muscle mass, physical strength, sexual function, and libido [32]. In a study of men undergoing treatment with TU, there was an increase in libido, vigour and vitality, sleep quality, a reduction in waist circumference, and a decrease in severity of ED [33]. Therefore, TRT in hypogonadal men may be a valuable tool to restore a physiological balance and achieve sexual pleasure as a component of well-being.

We hypothesised that TRT would improve both psychological and physical features that contribute to the long-term HRQoL in men with LOH.

Patients and methods

From November 2004, 261 patients (mean age 58 years) diagnosed with LOH were treated with long-acting TU (Nebido®, Bayer Pharma, Berlin, Germany) in a prospective observational and longitudinal registry study. All patients gave their written informed consent to be included in the study, which was conducted according to ethical guidelines as formulated by the German ‘Arztekammer’ (the German Medical Association) for observational studies and followed the principles outlined in the Helsinki Declaration of 1975, as revised in 1983. Men with a TT concentration of ≤3.5 ng/mL (12 nmol/L) and documented symptoms of ED (Sexual Health Inventory for Men (SHIM) score of ≤21) met the inclusion criteria. Men received i.m. injections of 1000 mg TU at day 1 (~3 weeks after diagnosis), week 6 and every 3 months thereafter. Patients were entered into a cumulative registry database once they had received treatment for at least 1 year and followed for up to 5 years. The average treatment period was 4.25 years.

Assessment of outcome

To assess the effect of long-term TU treatment, health quality indicators including the IPSS, the five-item version of the IIEF (IIEF-5), the Aging Males’ Symptoms (AMS) scale, and the percentage of patients reporting...
joint and muscle pain were measured among the study population at baseline and at every subsequent visit. The means were then calculated and plotted over time in parallel with mean TT levels. A $P < 0.05$ was considered to indicate statistical significance.

**Results**

The mean IPSS measured at baseline was 10.35, which fell significantly within the first 3 months to 9.5 ($P < 0.05$). This then decreased steadily over the remainder of the trial period and measured 7.22 after 63 months of TRT (Fig. 1).

The mean AMS score measured 54.27 at baseline and dropped dramatically to 37.42 within the first 3 months of the trial ($P < 0.05$). The mean AMS score subsequently fell gradually to 28.66 by the end of the trial (Fig. 2).

At baseline the mean IIEF-5 score was 7.8 and increased to 13.31 over the first 3 months of the trial. By 9 months the mean IIEF-5 score was 17.55 and by the end of the trial was 21.96 (Fig. 3).

58% of patients reported joint pain at the beginning of the study, which dropped to 46% after 3 months of TRT, and dropped again to 22% after 9 months. By the end of the trial period at 63 months the percentage of patients reporting joint pain was just 1% (Fig. 4). Additionally, 60% of patients reported muscle pain at the start of the study, which dropped to ≈50% after 3 months and fell to a remarkably low level by the end of the study period.

TT levels increased over the first 3 months of the trial from 2.23 ng/mL (7.73 nmol/L) at baseline to 4.82 ng/mL (16.71 nmol/L) after 3 months, reflecting the changes seen in the health quality indicator scores. After 63 months of treatment, the mean TT levels were 5.39 ng/mL (18.69 nmol/L; Figs. 1–4).

**Discussion**

In all, 58% of patients reported joint pain at the beginning of the study, which dropped to 46% after 3 months of TRT, and dropped again to 22% after 9 months. By the end of the trial period at 63 months the percentage of patients reporting joint pain was just 1% (Fig. 4). Additionally, ≈60% of patients reported muscle pain at the start of the study, which dropped to ≈50% after 3 months and fell to a remarkably low level by the end of the study period.

TT levels increased over the first 3 months of the trial from 2.23 ng/mL (7.73 nmol/L) at baseline to 4.82 ng/mL (16.71 nmol/L) after 3 months, reflecting the changes seen in the health quality indicator scores. After 63 months of treatment, the mean TT levels were 5.39 ng/mL (18.69 nmol/L; Figs. 1–4).

In the present prospective, observational and longitudinal study, we have shown that long-term treatment with TU in men with LOH results in a sustained...
improvement in health quality indicators including the IPSS, AMS, IIEF-5 scale, and reported joint and muscle pain, alongside increased TT levels, contributing to an improved, long-term HRQoL.

Our present findings confirm previous studies in which testosterone is shown to significantly improve sexual function and vitality, physical pain, general health, and the overall HRQoL in men with testosterone deficiency [33–37,26,38]. Such studies provide evidence that testosterone improves the HRQoL in hypogonadal men [39–41] and may explain the increase in physical activity that is often associated with TRT [42].

In the present study, both the AMS score and IPSS fell significantly within the first 3 months of the trial. In a previous study, erectile function was found to improve as early as 3 weeks and the AMS score as early as 6 weeks after the initiation of TU treatment [43]. However, it can take up to 12 months for maximum results [43], showing clearly that long-term treatment with TU is required to achieve optimal effects. Thus, the duration of the present study, which allows time for the optimal effects of TU to be observed, provides a useful timescale to gain a thorough understanding of the time course of testosterone effects from which hypogonadal patients will benefit. The time course of IPSS improvement has been less well studied than other parameters of HRQoL. One study found a significant reduction in the IPSS at 3 months after commencing TU treatment [44].

The results of several randomised, placebo-controlled trials observing the effect of TRT on symptoms of depression and HRQoL, as assessed by various subjective questionnaires, have produced mixed results; some found no effect of testosterone [45,46], whereas other studies did find beneficial effects of testosterone on depression in men [26,47]. However, these trials were short-term and therefore any indirect actions of testosterone to improve HRQoL, e.g. by improving the symptoms of metabolic syndrome and reducing obesity [39], may not be apparent. As such, longer trials may be required for the positive effects of testosterone to materialise. Moreover, several studies included healthy men with TT levels of >12.5 nmol/L [45,48]. In the present study, the greatest improvements were seen within the first 3 months, an effect that was sustained throughout the remainder of the trial period, which lasted on average 4.25 years.

There are some potential limitations of the present study. The TT levels measured were trough levels, as blood samples were taken before the next TU injection, i.e. 3 months after the previous TU injection. Evidence from pharmacokinetic studies shows that TT levels between injections peak in the second week after injection [49,50] and thus any dose-dependent effects seen may reflect this. A recent study demonstrated that in addition to testosterone, oestradiol plays an important role in the regulation of body fat and sexual function, thus a deficiency in this hormone may underlie a number of sequelae of male hypogonadism [51]. Oestradiol levels were not measured in the present study and so this may be considered a further limitation of the study. One final limitation of the present study is the nature of the registry design. This single-centre, open-label study is not a randomised controlled study and therefore limits the scope of interpretation of the presented findings. However, our present findings were recently confirmed in a small placebo-controlled study in which 20 obese hypogonadal men with LUTS were treated for 5 years with TU [52]. Although no changes in IPSS were seen, TT levels increased significantly with TRT [52].

In conclusion, this prospective, observational and longitudinal analysis shows a clear improvement in the long-term HRQoL, both physically and psychologically, in men with LOH treated with TU.

Conflicts of interest

Farid Saad, beside his position as University Professor, is an employee at Global Medical Affairs Men’s Healthcare, Bayer Pharma AG, Berlin, Germany.

All other authors have no conflicts of interest to declare.

Source of funding

None.

Acknowledgements

Editorial support for the manuscript was provided by Astra-Health, www.astra-health.co.uk.

References

[1] Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. EAU Guidelines on male hypogonadism. Available at: <http://uroweb.org/guideline/male-hypogonadism/> [accessed 27.7.2015].
[2] Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko Y, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:5–15.
[3] Harman SM, Metter EJ, Tobin JD, Pearson J. Longitudinal study of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724–31.
[4] Purifoy FE, Koopmans LH, Mayers DM. Age differences in serum androgen levels in normal adult males. Hum Biol 1981;53:499–511.
[5] Mulligan T, Frick MF, Zuraw QC, Stenhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–9.
[6] Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, et al. Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med 2011;8:2098–105.
[7] Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, et al. Low levels of androgens in men with erectile dysfunction. J Sex Med 2008;5:2454–63.
[8] Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of lifestyle changes on erectile
dysfunction in obese men: a randomized controlled trial. J Am Med Assoc 2004;291:2978–84.

9. Riedner CE, Rhode EP, Ribeiro EP, Fuchs SC. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 2006;176:1519–23.

10. Wing RR, Rosen RC, Fava JL, Bahnmus J, Brancati F, Gendran III IN, et al. Effects of weight loss intervention on erectile dysfunction in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med 2010;7:156–65.

11. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011;96:2341–53.

12. Lyon CJ, Law RE, Sueshe WA. Mini-review: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195–200.

13. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–55.

14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–28.

15. Corona G, Monami M, Rastrelli G, Aversa A, Vignozzi L, Mannucci E, et al. Testosterone supplementation on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966–72.

16. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2010;7:871–82.

17. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612–27.

18. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497–501.

19. Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 2006;24:639–44.

20. Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Yassin AA, Saad F, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2005;2:272–83.

21. Aversa A, Brazzelli R, Franchon, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010;33:776–83.

22. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497–501.

23. Aversa A, Brazzelli R, Franchon, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010;33:776–83.

24. Almeida OP, Yeap BB, Hankey GJ, Jamrozik K, Flicker L. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Endocrinol Metab 2013;98:220–9.

25. Luppino FS, de Wit LM, Bouvy PF, Emmeloot LJ, Cuijpers P, Kalisch S, et al. Testosterone and metabolic syndrome: an observational, long-term registry study. J Sex Med 2013;10:1579–88.

26. Fabbri M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612–27.

27. Yassin AA, Saad F, Thaiss A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727–35.

28. Trumpp AM, Haider A, Gooren LJ, Padungtod P, Saad F. A safety study of testosterone treatment in elderly men with hypogonadism and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589–98.

29. Saad F, Aversa A, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.

30. Haider A, Gooren LJ, Padungtod P, Saad F. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. Andrologia 2010;42:349–55.

31. Bhasin S, Channer KS, Fuchs SC, Hahn J, Hendrix SC, Hsia DS, et al. Testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. J Clin Endocrinol Metab 2013;98:604–11.

32. Yassin AA, Saad F, Thaiss A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727–35.

33. Trumpp AM, Haider A, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.

34. Saad F, Aversa A, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.

35. Fabbri M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612–27.

36. Yassin AA, Saad F, Thaiss A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727–35.

37. Haider A, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.

38. Saad F, Aversa A, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85.

39. Fabbri M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612–27.

40. Yassin AA, Saad F, Thaiss A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727–35.

41. Trumpp AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. J Sex Med 2013;10:1579–88.

42. Yassin AA, Saad F, Thaiss A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727–35.

43. Trumpp AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. J Sex Med 2013;10:1579–88.

44. Yassin AA, Saad F, Thaiss A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727–35.
Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. *J Am Med Assoc* 2008;299:39–52.

Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. *J Clin Psychiatry* 2001;62:406–12.

Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). *J Clin Psychiatry* 2009;70:1009–16.

Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab* 2003;88:2673–81.

Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph M, Oettel M, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. *J Clin Endocrinol Metab* 2004;89:5429–34.

Von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. *J Androl* 2002;23:419–25.

Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med* 2013;369:1011–22.

Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. *Urology* 2013;83:167–73.